Page 51 - Read Online

Girotti et al. J Cancer Metastasis Treat 2020;6:52 I http://dx.doi.org/10.20517/2394-4722.2020.107 Page 13 of 15

Authors’ contributions
Wrote the manuscript and secured funding for the ALA-PDT/iNOS/NO studies carried out in his
laboratory: Girotti AW
Planned and carried out most of the experiments represented in Figures 2-5, and made helpful suggestions
about the manuscript: Fahey JM
Secured funding for the PDT-bystander studies and offered helpful suggestions about the manuscript:
Korytowski W

Financial support and sponsorship
The research of two authors (Albert W. Girotti and Witold Korytowski) was supported by the following
grants: USPHS Grant CA70823 from the National Cancer Institute, BSC Grant FP12605, and Rock River
Grant FP14869 from the MCW Cancer Center (to Albert W. Girotti); NCN Grant 2017/27/B/NZ5/02620 (to
Witold Korytowski).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Neuropathol 2007;114:97-
109.
2. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. The Lancet 2003;361:323-31.
3. Wen PY, Kesari S. Malignant gliomas in adults. New Engl J Med 2008;359:492-507.
4. Stewart DJ, Molep JM, Eapen L, et al. Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological
considerations and results of early studies. Int. J Radiat Oncol Biol Phys 1994;28:531-42.
5. Yang LJ, Zhou CF, Lin ZX. Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review. Cancer
Investig 2014;32:31-6.
6. Miranda A, Blanco-Prieto M, Sousa J, Pais A, Vitorino C. Breaching barriers in glioblastoma. Part 1: molecular pathways and novel
treatment approaches. Int J Pharm 2017;531:372-88.
7. Bouzinab K, Summers H, Zhang J, et al. In serach of effective therapies to overcome resistance to temozolomide in brain tumors. Cancer
Drug Resist 2019;2:1018-31.
8. Quirk BJ, Brandal G. Donlon S, et al. Photodynamic therapy (PDT) for brain tumors: where do we stand? Photodiagn Photodyn Ther
2015; 12:530-44.
9. Bechet D, Mordon SR, Guillemin F, Barberi-Heyob MA, Photodynamic therapy of malignant brain tumours: a complementary approach
to conventional therapies. Cancer Treat Rev 2014;40:229-41.
10. Cramer SW, Chen CC. Photodynamic therapy for the treatment of glioblastoma. Front Surg 2020;6:81.
11. Casas A, Perotti C, Ortel B, et al. Tumor cell lines resistant to ALA-mediated photodynamic therapy and possible tools to target surviving
cells. Int J Oncol 2006;29:397-405.
12. Casas A, Di Venosa, G, Hasan T, Batlle A. Mechanisms of resistance to photodynamic therapy. Curr Med Chem 2011;18:2486-515.
13. Girotti AW. Upregulation of nitric oxide in tumor cells as a negative adaptation to photodynamic therapy. Lasers in Surg Med
2018;50:590-8.
14. Fahey JM, Girotti AW. Nitric oxide antagonism to anti-glioblastoma photodynamic therapy: mitigation by inhibitors of nitric oxide
generation. Cancers 2019;11:231.
15. Thomas DD, Liu X, Kantrow SP, Lancaster JR Jr. The biological lifetime of nitric oxide: implications for the perivascular dynamics of
NO and O2. Proc Natl Acad Sci U S A 2001;98:355-60.
16. Gantner BN, LaFond KM, Bonini MG. Nitric oxide in cellular adaptation and disease. Redox Biol 2020;34:101550.